サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1361549

マラリア治療薬市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年

Malaria Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Drug Type, By Drug Formulation, By End User, By Distribution Channel By Region, and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 84 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

マラリア治療薬市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 84 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のマラリア治療薬市場は、世界のマラリア撲滅に向けた研究開発の継続的な投資により、2028年の予測期間中に大きく成長すると予測されます。

世界保健機関（WHO）によると、2020年には世界で推定2億2,900万人のマラリア患者が発生し、推定40万9,000人が死亡しました。

マラリアは、感染した雌の蚊に刺されることで人に感染する寄生虫によって引き起こされる、生命を脅かす可能性のある病気です。マラリアの原因となる寄生虫はマラリア原虫の一種で、中でもマラリア原虫が最も致死率が高いです。マラリアは熱帯および亜熱帯地域、特にサハラ以南のアフリカで流行しており、罹患率および死亡率の主要原因となっています。マラリアの治療には抗マラリア薬が使用されるが、これは感染の種類や重症度によって異なります。マラリアに感染した疑いがある場合は、速やかに医師の診察を受けることが重要です。マラリアは重篤な疾患であり、迅速かつ適切な治療を行わなければ命に関わることもあります。

利用可能なカスタマイズ：

TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 マラリア治療薬の世界市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別（アルテミシニンベースの併用療法（ACT）、キニーネ、クロロキン、その他）
    • 剤形別（錠剤、カプセル剤、注射剤、その他）
    • 流通チャネル別（小売薬局、病院、オンライン薬局）
    • 地域別
    • 企業別（2022年）
  • 製品マップ
    • 薬剤タイプ別
    • 剤形別
    • 販売チャネル別
    • 地域別

第7章 北米マラリア治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別（キニーネ、クロロキン、その他）
    • 剤形別
    • 流通チャネル別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州マラリア治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別（キニーネ、クロロキン、その他）
    • 剤形別
    • 流通チャネル別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋マラリア治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別（キニーネ、クロロキン、その他）
    • 剤形別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域国別分析
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • ベトナム
    • ミャンマー

第10章 南米マラリア治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別（キニーネ、クロロキン、その他）
    • 剤形別
    • 流通チャネル別
    • 国別
  • 南米：国別分析
    • ブラジル
    • コロンビア

第11章 中東・アフリカのマラリア治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別（キニーネ、クロロキン、その他）
    • 剤形別
    • 流通チャネル別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • トルコ
    • エジプト
    • ナイジェリア

第12章 市場力学

  • 促進要因
    • マラリアの高い蔓延率
    • 意識の高まり
  • 課題
    • 高コストと入手困難性
    • 一般市民の認識不足

第13章 市場動向と発展

  • デジタル治療薬の利用
  • 遺伝子検査の利用の増加
  • 併用療法の増加

第14章 マラリア治療薬の世界市場SWOT分析

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 競合情勢

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Novartis AG
    • Sanofi S.A
    • Pfizer Inc
    • GlaxoSmithKline Plc
    • Merck & Co Inc
    • F. Hoffmann-La Roche AG
    • Medicines for Malaria Venture
    • 60°Pharmaceuticals, Inc
    • Cipla Limited
    • Ajanta Pharma Limited

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 15002

Global Malaria Therapeutics market is anticipated to grow considerably in the forecast period of 2028 due to the ongoing Investments in malaria research and development for eradicating malaria globally. According to the World Health Organization (WHO), in 2020, there were an estimated 229 million cases of malaria globally, with an estimated 409,000 deaths.

Malaria is a potentially life-threatening disease caused by parasites transmitted to humans through the bites of infected female mosquitoes. The parasites responsible for malaria are of the Plasmodium species, with Plasmodium falciparum being the most deadly. Malaria is prevalent in tropical and subtropical regions, particularly in sub-Saharan Africa, where it is a leading cause of morbidity and mortality. Treatment for malaria involves the use of antimalarial medications, which can vary depending on the type and severity of the infection. It is important to seek prompt medical attention if you suspect you have contracted malaria. Malaria is a serious disease and can be fatal if not treated promptly and appropriately.

Malaria therapeutics have a significant impact on patients who are infected with malaria. Malaria therapeutics help to alleviate the symptoms of the disease and prevent it from progressing to severe disease. Effective treatment can reduce the duration and severity of the illness, and prevent complications and long-term health problems. In addition to their direct impact on patients, malaria therapeutics also have broader impacts on public health and society, thereby supporting the growth of global malaria therapeutics market. Effective treatment can reduce the spread of the disease and prevent the development of drug-resistant strains of the parasite. This, in turn, can help to reduce the burden of the disease on healthcare systems and economies.

However, access to malaria therapeutics remains a significant challenge in many regions of the world where malaria is endemic, thereby hampering the growth of global malaria therapeutics market. Limited healthcare infrastructure, high treatment costs, and other barriers to access can prevent patients from receiving the care they need. Efforts to improve access to malaria therapeutics, such as through the development of affordable and accessible drugs and diagnostic tests, are crucial for improving patient outcomes and reducing the global burden of malaria. In 2020, 46 countries reported an increase in malaria cases, with 26 of these countries reporting more than a 20% increase. Children under the age of five are the most vulnerable group affected by malaria, accounting for an estimated 67% of all malaria deaths worldwide in 2020.

Growing incidence of malaria is boosting the Malaria Therapeutics Market

Increased demand for malaria therapeutics as the number of malaria cases increases, there is a greater demand for effective treatments. This presents a significant market opportunity for pharmaceutical companies developing malaria therapeutics.Malaria is a costly disease to treat, both in terms of direct medical expenses and lost productivity. As the incidence of malaria increases, healthcare systems may struggle to keep up with the demand for treatment and prevention, which could lead to increased costs. Malaria can cause severe illness and death, particularly among young children and pregnant women. The growing incidence of malaria means that more people are at risk of contracting the disease, which could lead to increased morbidity and mortality.

Malaria is a significant barrier to economic development in many countries, particularly those in sub-Saharan Africa. The disease can lead to lost productivity, increased healthcare costs, and decreased investment. As the incidence of malaria increases, these impacts may become more pronounced.

Malaria is a significant public health problem in many tropical and subtropical regions of the world, particularly in sub-Saharan Africa, where more than 90% of malaria cases and deaths occur. However, malaria also affects other parts of the world, including Asia, Latin America, and the Middle East. The incidence of malaria has been increasing in several countries in recent years, partly due to factors such as climate change, insecticide resistance, and the lack of access to effective prevention and treatment. In addition, political instability, Efforts to control and eliminate malaria include the use of insecticide-treated bed nets, indoor residual spraying, and antimalarial drugs. However, these efforts face several challenges, including limited funding, inadequate healthcare infrastructure, and the emergence of drug-resistant strains of the parasite.

Therefore, the growing incidence of malaria in several countries is a significant public health challenge that requires a comprehensive and sustained effort to address, thereby supporting the growth of global malaria therapeutics market.

Increasing investment in malaria research is Driving the Demand for Malaria Therapeutics in the Market

Increasing investment in malaria research is driving the demand for malaria therapeutics in the market. Investment in malaria research can lead to the development of new and improved malaria therapeutics, such as drugs and vaccines. These therapeutics can then be marketed and sold to individuals and organizations that are involved in the prevention and treatment of malaria.

In addition to driving demand for malaria therapeutics, increased investment in malaria research can also lead to the creation of new businesses and job opportunities in the pharmaceutical industry. This can have a positive impact on the economy and provide benefits for individuals and communities. Additionally, investment in malaria research is essential to address the global burden of malaria and improve the health outcomes of individuals who are affected by the disease. By driving demand for malaria therapeutics, such investment can play a critical role in achieving these goals.

Investment in malaria research can also lead to increased access to malaria interventions, such as mosquito nets, diagnostic tests, and antimalarial drugs. This can help prevent the spread of the disease and reduce the number of cases and deaths. Investment in malaria research can help strengthen health systems in malaria-endemic countries, leading to improved health outcomes for the population. This can include training healthcare workers, improving healthcare infrastructure, and increasing access to healthcare services.

Malaria disproportionately affects the most vulnerable populations, such as children under five and pregnant women. Increasing investment in malaria research can help reduce health inequities by improving access to prevention and treatment options for these populations.

Investment in malaria research can lead to the development of effective interventions such as vaccines, drugs, and insecticides. These interventions can then be used across multiple countries, leading to a reduction in the burden of malaria in those regions.

Furthermore, Investment in malaria research also lead to increased collaboration between researchers, healthcare providers, and governments across multiple countries. This collaboration can help share best practices and information, leading to better prevention and treatment of malaria across borders.

Additionally, Investment in malaria research can also have an impact on global health security. Malaria is a global health threat, and investing in research can help prevent the spread of the disease across borders and reduce the risk of epidemics.Malaria can cause significant morbidity, leading to long-term health problems in those who survive the disease. Investing in malaria research can help improve health outcomes by reducing the number of cases and the severity of the disease.

Favorable Government initiatives and Policies Drives the Malaria Therapeutics Market Growth

Favorable government initiatives and policies can play a significant role in driving the growth of the malaria therapeutics market. Malaria is a life-threatening disease that affects millions of people globally, particularly in developing countries. To combat the disease, governments across the world have launched various initiatives to promote the development and distribution of malaria therapeutics.

For instance, many governments have allocated significant funds for research and development activities focused on developing effective malaria therapeutics. In addition, governments have also launched programs to increase the accessibility of malaria medications to patients. This includes initiatives aimed at improving the supply chain, reducing the cost of medicines, and increasing awareness among patients.

Furthermore, various policies, such as tax incentives and regulatory frameworks, have been put in place to encourage investment in the global malaria therapeutics market. These policies can help to attract pharmaceutical companies and other stakeholders to invest in research and development activities, leading to the development of new and more effective malaria therapeutics. One of the most significant government initiatives is the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund is a partnership between governments, civil society, the private sector, and affected communities, and it provides funding for programs aimed at reducing the burden of malaria, among other diseases. In 2002, the Global Fund has committed over USD13 billion to malaria programs, and this funding has been crucial in supporting malaria control efforts worldwide.

Another important government initiative is the Roll Back Malaria Partnership, which is a global initiative aimed at coordinating and strengthening efforts to reduce the burden of malaria. The partnership is led by the World Health Organization and includes a wide range of stakeholders, including governments, international organizations, and civil society. Through the Roll Back Malaria Partnership, governments have committed to providing universal access to malaria prevention and treatment by 2030.

In addition to these global initiatives, many governments have also launched national programs aimed at combating malaria. For example, the government of Nigeria launched the National Malaria Elimination Program in 2016, with the goal of reducing the burden of malaria by 2020. The program includes a wide range of activities, such as the distribution of insecticide-treated bed nets, the provision of malaria diagnosis and treatment services, and the promotion of community-based interventions.

Governments have also implemented policies aimed at promoting the development and distribution of malaria therapeutics. For example, many countries have implemented policies aimed at reducing the cost of malaria medications. In some cases, governments have even provided free or subsidized medications to patients. In addition, many governments have implemented regulatory frameworks aimed at ensuring the quality and safety of malaria therapeutics.

Hence, the support of government initiatives has been crucial in driving the development and distribution of malaria therapeutics. These initiatives have provided funding and support for research and development activities, as well as for programs aimed at improving access to malaria prevention and treatment services. While there is still much work to be done in the fight against malaria, these government initiatives provide hope for a future where malaria is no longer a major public health concern. Hence creating lucrative opportunities for the growth of global malaria therapeutics market in the forecast period.

Market Segmentation

Global Malaria Therapeutics market is segmented based on drug type, drug formulation, distribution channel, and region. Based on drug type, global malaria therapeutics market is segmented into artemisinin-based combination therapy (ACT), quinine, chloroquine, and others. Based on drug formulation, the global malaria therapeutics market is fragmented into tablets, capsules, injectables, and Others. Based on distribution channel, the global malaria therapeutics market is segmented into retail pharmacies, hospitals, online pharmacies. Based on region, global malaria therapeutics market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Novartis AG, Sanofi S.A, Pfizer Inc, GlaxoSmithKline Plc, Merck & Co Inc, F. Hoffmann-La Roche AG, Medicines for Malaria Venture, 60° Pharmaceuticals, Inc, Cipla Limited, Ajanta Pharma Limited are some of the key players of global malaria therapeutics market.

Report Scope:

In this report, global Malaria Therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

  • Malaria Therapeutics Market, By Drug Type:

Artemisinin-based combination therapy (ACT)

Quinine

Chloroquine

Others

  • Malaria Therapeutics Market, By Drug Formulatuion:

Tablets

Capsules

Injectables

Others

  • Malaria Therapeutics Market, By Distribution Channel:

Retail pharmacies

Hospitals

Online pharmacies

  • Malaria Therapeutics Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • France
  • Germany
  • United Kingdom
  • Spain
  • Italy

Asia-Pacific

  • India
  • South Korea
  • Japan
  • Australia
  • Vietnam
  • Indonesia
  • Myanmar

South America

  • Brazil
  • Colombia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Turkey
  • Nigeria

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global Malaria Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Malaria Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 6.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 6.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Product Map
    • 5.3.1 By Drug Type
    • 5.3.2 By Drug Formulation
    • 5.3.5 By Distribution Channel
    • 5.3.6 By Region

7. North America Malaria Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 7.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 7.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Malaria Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Drug Formulation
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Malaria Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Drug Formulation
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Malaria Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Drug Formulation
        • 7.3.3.2.3. By Distribution Channel

8. Europe Malaria Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 8.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 8.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Malaria Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Drug Formulation
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Germany Malaria Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Drug Formulation
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. United Kingdom Malaria Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecasty
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Drug Formulation
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Italy Malaria Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Drug Formulation
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Malaria Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Drug Formulation
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Malaria Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 9.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 9.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. India Malaria Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Drug Formulation
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Japan Malaria Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Drug Formulation
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Korea Malaria Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Drug Formulation
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Australia Malaria Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Type
        • 9.3.4.2.2. By Drug Formulation
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Indonesia Malaria Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Type
        • 9.3.5.2.2. By Drug Formulation
        • 9.3.5.2.3. By Distribution Channel
    • 9.3.6. Vietnam Malaria Therapeutics Market Outlook
      • 9.3.6.1. Market Size & Forecast
        • 9.3.6.1.1. By Value
      • 9.3.6.2. Market Share & Forecast
        • 9.3.6.2.1. By Drug Type
        • 9.3.6.2.2. By Drug Formulation
        • 9.3.6.2.3. By Distribution Channel
    • 9.3.7. Myanmar Malaria Therapeutics Market Outlook
      • 9.3.7.1. Market Size & Forecast
        • 9.3.7.1.1. By Value
      • 9.3.7.2. Market Share & Forecast
        • 9.3.7.2.1. By Drug Type
        • 9.3.7.2.2. By Drug Formulation
        • 9.3.7.2.3. By Distribution Channel

10. South America Malaria Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 10.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 10.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Malaria Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Drug Formulation
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Malaria Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Drug Formulation
        • 10.3.2.2.3. By Distribution Channel

11. Middle East and Africa Malaria Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 11.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 11.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Malaria Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Type
        • 11.3.1.2.2. By Drug Formulation
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Malaria Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Type
        • 11.3.2.2.2. By Drug Formulation
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Malaria Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Type
        • 11.3.3.2.2. By Drug Formulation
        • 11.3.3.2.3. By Distribution Channel
    • 11.3.4. Turkey Malaria Therapeutics Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Type
        • 11.3.4.2.2. By Drug Formulation
        • 11.3.4.2.3. By Distribution Channel
    • 11.3.5. Egypt Malaria Therapeutics Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Drug Type
        • 11.3.5.2.2. By Drug Formulation
        • 11.3.5.2.3. By Distribution Channel
    • 11.3.6. Nigeria Malaria Therapeutics Market Outlook
      • 11.3.6.1. Market Size & Forecast
        • 11.3.6.1.1. By Value
      • 11.3.6.2. Market Share & Forecast
        • 11.3.6.2.1. By Drug Type
        • 11.3.6.2.2. By Drug Formulation
        • 11.3.6.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
    • 12.1.1 High prevalence of malaria
    • 12.1.2 Growing Awareness
  • 12.2. Challenges
    • 12.2.1 High Cost and not always readily available
    • 12.2.2 Lack of Public Awareness

13. Market Trends & Developments

  • 13.1. Use of digital therapeutics
  • 13.2. Increasing use of genetic testing
  • 13.3. Increasing use of Combination Therapies

14. Global Malaria Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Product Offerings
  • 16.3. Recent Developments
  • 16.4. Financials (As Reported)
  • 16.5. Key Personnel
  • 16.6. SWOT Analysis
    • 16.6.1. Novartis AG
    • 16.6.2. Sanofi S.A
    • 16.6.3. Pfizer Inc
    • 16.6.4. GlaxoSmithKline Plc
    • 16.6.5. Merck & Co Inc
    • 16.6.6. F. Hoffmann-La Roche AG
    • 16.6.7. Medicines for Malaria Venture
    • 16.6.8. 60° Pharmaceuticals, Inc
    • 16.6.9. Cipla Limited
    • 16.6.10. Ajanta Pharma Limited

17. Strategic Recommendations

18. About Us & Disclaimer